Related Experiment Video

Updated: Jul 14, 2026

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France

M Debouverie1, S Louis, S Pittion-Vouyovitch

  • 1Dept. of Neurology, Central Hospital, 54000, Nancy, France. m.debouverie@chu-nancy.fr

Journal of Neurology
|June 21, 2007
PubMed

Insights

This study on progressive multiple sclerosis (MS) found no significant differences between primary progressive MS (PPMS) and relapsing progressive MS (PRMS) in disease progression. Patient characteristics like sex and age at onset did not influence disability progression rates.

Area of Science:

  • Neurology
  • Clinical Research
  • Epidemiology

Background:

  • Multiple sclerosis (MS) presents with various subtypes, including primary progressive MS (PPMS) and relapsing progressive MS (PRMS).
  • Understanding the distinct characteristics and progression patterns of these subtypes is crucial for effective patient management and therapeutic development.
  • Previous research has explored differences, but a comprehensive analysis of progressive MS subtypes in a defined population is warranted.

Purpose of the Study:

  • To investigate patient characteristics, disease progression, and risk factors in individuals with a progressive onset of multiple sclerosis.
  • To compare disease progression trajectories between primary progressive MS (PPMS) and relapsing progressive MS (PRMS) patients.
  • To identify demographic and clinical factors influencing the rate of disability accumulation in progressive MS.

Main Methods:

  • A longitudinal, population-based study was conducted on 359 patients with progressive onset of MS in Lorraine, France.
  • Patients were categorized into PPMS (n=252) and PRMS (n=107) groups.
  • Outcomes included time to reaching specific disability status scale (DSS) scores (4, 6, 7) and time between DSS scores, analyzing the influence of sex, age, and onset symptoms.

Main Results:

  • No significant differences were observed in demographic data or time to reaching DSS scores between PPMS and PRMS patients, suggesting the distinction may be unnecessary.
  • The median age at onset was 42.7 years, notably lower for males (40.5 years) than females (44.2 years).
  • Median times to DSS scores 4, 6, and 7 were 3.0, 9.9, and 17.0 years, respectively. A cane was needed by 25% of patients at 5 years and 75% at 15 years post-onset.

Conclusions:

  • The distinction between PPMS and PRMS may not be clinically relevant regarding disease progression and demographic factors.
  • Sex and age at onset did not significantly influence the progression rate to higher disability levels.
  • Further research should focus on unified management strategies for progressive MS, irrespective of subtype, and explore other potential influencing factors on disease trajectory.

More Related Videos

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...